Yasir Loai1, Nurus Sakib1, Rafal Janik2, Warren D. Foltz3, Hai-Ling Margaret Cheng, 14
1The Hospital for Sick Children, Toronto, Ontario, Canada; 2Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; 3University Health Network, Toronto, Ontario, Canada; 4Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
Positive T1 contrast MRI offers improved specificity and spatial delineation over conventional negative-contrast imaging, and gadolinium oxide (Gd2O3) nanoparticles have shown promise as a sensitive T1 agent for labeling. However, it is not known if signal enhancement in labeled cells is maintained at high field strengths, where relaxivity is known to decline. This study explores the potential of Gd2O3 for positive-contrast MRI at 7 Tesla. It is demonstrated in human aortic endothelial cells that large amounts of Gd2O3 were ingested spontaneously and that significant and stable positive T1 contrast on cells was achieved for at least 7 days.